Filamon Limited, an Australian biotech company focused on developing next-gen anti-inflammatory drugs, has announced its breakthrough dementia treatment. ALPHA-003 is designed to preserve the integrity of vital brain cell structures and protect them against destruction caused by brain inflammation.

In healthy neurons, the tau protein stabilizes microtubules, crucial tube-like structures that, together with neurofilaments, maintain the neurons' shape and provide mechanical support. However, when it's modified, tau can form toxic aggregates – tangles that degrade these key structures. This is seen in a group of diseases called tauopathies, such as dementia, including Alzheimer's disease, and chronic traumatic encephalopathy (CTE).